




**Research Unit**  
Press Information Bureau  
Government of India

## India's Pharma Sector Gets a Shot of Growth at 7.8% in April

### From Generic Drugs to Global Vaccines, Transforming Lives Worldwide

18<sup>th</sup> May, 2025

Imagine a world where quality medicines cost less than a cup of chai, and every village has access to life-saving drugs. That's the reality India is building. From 2014 to 2024 the pharma sector has transformed into a global health leader affordable, innovative, and inclusive. Looking ahead, experts at India Ratings part of the Fitch Group, expect revenue to grow **7.8% year-on-year in April 2025** driven by strong demand and new products.



India's pharmaceutical industry is a global giant ranking **3rd in volume and 14th in value**. It's the largest supplier of generic medicines providing 20% of the world's supply and a key player in affordable vaccines. In 2023-24, the sector's turnover hit ₹4,17,345 crore growing steadily at over 10% annually for the past five years. For the common man this means more medicines at lower prices, better healthcare and jobs in factories and labs across the country. From small towns to big cities, India's pharma growth is creating opportunities and saving lives.

The government's smart schemes are the backbone of this success. The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) runs **15,479 Jan Aushadhi Kendras**, offering generic medicines at prices up to 80% lower than branded ones. A heart medicine that once cost ₹500 might now cost ₹100! The Production Linked Incentive (PLI) Scheme for Pharmaceuticals with ₹15,000 crore, supports 55 projects to make high-end drugs like cancer and diabetes medicines right here in India. Another PLI scheme with ₹6,940 crore focuses on raw materials like Penicillin G, reducing our need for imports. The PLI for **Medical Devices backed by ₹3,420 crore** is boosting production of tools like MRI machines and heart implants.

Then there's the Promotion of Bulk Drug Parks scheme with ₹3,000 crore building mega hubs in Gujarat, Himachal Pradesh and Andhra Pradesh to make medicines cheaper and faster. The Strengthening of Pharmaceuticals Industry (SPI) Scheme with ₹500 crore, funds research and upgrades labs, helping Indian companies compete globally. These efforts mean medicines are made in India, for India and for the world keeping costs low and quality high.

India's pharma sector supplies **55-60% of UNICEF's vaccines**, meeting 99% of WHO's DPT (Diphtheria, Whooping cough and Tetanus) vaccine demand, 52% for BCG (Bacillus Calmette-Guérin is a vaccine primarily used against TB), and 45% for measles. From Africa to America, Indian vaccines save millions. At home, these schemes create jobs for young Indians, from factory workers to scientists. Foreign investors are pouring in with **₹12,822 crore in 2023-24** alone, because they see India's potential. The government welcomes 100% foreign investment in medical devices and greenfield pharma projects, making India a hotspot for global companies.

India's pharmaceutical sector is more than an industry: it's a lifeline. With schemes like PMBJP, PLI, and Bulk Drug Parks, the Modi government is ensuring no one is left behind when it comes to healthcare. From affordable medicines at Jan Aushadhi Kendras to vaccines reaching the world, India is building a healthier, self-reliant future. As we step into Amrit Kaal, every Indian can take

pride in a nation that heals, innovates, and leads. The future of healthcare is here, and it's proudly Indian!

## References

- <https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2121425>
- <https://static.pib.gov.in/WriteReadData/specificdocs/documents/2025/jan/doc202516481901.pdf>
- [https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2121425#\\_ftn4](https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2121425#_ftn4)
- <https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2085345>

**Santosh Kumar/ Ritu Kataria/ Kamna Lakaria**